Characteristics and Outcome of


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
04 2020
Historique:
received: 15 10 2019
revised: 18 12 2019
accepted: 10 01 2020
pubmed: 12 1 2020
medline: 26 8 2021
entrez: 12 1 2020
Statut: ppublish

Résumé

AKT inhibitors have promising activity in

Identifiants

pubmed: 31924700
pii: 2159-8290.CD-19-1209
doi: 10.1158/2159-8290.CD-19-1209
pmc: PMC7125034
mid: NIHMS1550109
doi:

Substances chimiques

Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

526-535

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

©2020 American Association for Cancer Research.

Références

J Clin Oncol. 2016 Jun 1;34(16):1872-81
pubmed: 26926684
Cancer Discov. 2017 Aug;7(8):818-831
pubmed: 28572459
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Cell. 2017 Feb 9;168(4):584-599
pubmed: 28187282
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Nature. 2007 Jul 26;448(7152):439-44
pubmed: 17611497
Br J Cancer. 2008 May 6;98(9):1533-5
pubmed: 18392055
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Cancer Cell. 2018 Sep 10;34(3):427-438.e6
pubmed: 30205045
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
J Clin Oncol. 2016 Feb 10;34(5):419-26
pubmed: 26503204
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
J Clin Oncol. 2017 Jul 10;35(20):2251-2259
pubmed: 28489509
Science. 2019 Nov 8;366(6466):714-723
pubmed: 31699932
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
JAMA. 2019 Apr 9;321(14):1391-1399
pubmed: 30964529
Cancer Discov. 2019 Jan;9(1):OF7
pubmed: 30429128
Annu Rev Med. 2018 Jan 29;69:319-331
pubmed: 29120700

Auteurs

Lillian M Smyth (LM)

Memorial Sloan Kettering Cancer Center, New York, New York. lilsmyth@svhg.ie.

Qin Zhou (Q)

Memorial Sloan Kettering Cancer Center, New York, New York.

Bastien Nguyen (B)

Memorial Sloan Kettering Cancer Center, New York, New York.

Celeste Yu (C)

Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Eva M Lepisto (EM)

Dana-Farber Cancer Institute, Boston, Massachusetts.

Monica Arnedos (M)

Institut Gustave Roussy, Villejuif, France.

Michael J Hasset (MJ)

Dana-Farber Cancer Institute, Boston, Massachusetts.

Michele L Lenoue-Newton (ML)

Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

Natalie Blauvelt (N)

Memorial Sloan Kettering Cancer Center, New York, New York.

Semih Dogan (S)

Institut Gustave Roussy, Villejuif, France.

Christine M Micheel (CM)

Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

Chetna Wathoo (C)

The University of Texas MD Anderson Cancer Center, Houston, Texas.

Hugo Horlings (H)

Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands.

Jan Hudecek (J)

Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands.

Benjamin E Gross (BE)

Memorial Sloan Kettering Cancer Center, New York, New York.

Ritika Kundra (R)

Memorial Sloan Kettering Cancer Center, New York, New York.

Shawn M Sweeney (SM)

American Association for Cancer Research, Philadelphia, Pennsylvania.

JianJiong Gao (J)

Memorial Sloan Kettering Cancer Center, New York, New York.

Nikolaus Schultz (N)

Memorial Sloan Kettering Cancer Center, New York, New York.

Andrew Zarski (A)

Memorial Sloan Kettering Cancer Center, New York, New York.

Stuart M Gardos (SM)

Memorial Sloan Kettering Cancer Center, New York, New York.

Jocelyn Lee (J)

American Association for Cancer Research, Philadelphia, Pennsylvania.

Seth Sheffler-Collins (S)

American Association for Cancer Research, Philadelphia, Pennsylvania.

Ben H Park (BH)

Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

Charles L Sawyers (CL)

Memorial Sloan Kettering Cancer Center, New York, New York.

Fabrice André (F)

Institut Gustave Roussy, Villejuif, France.

Mia Levy (M)

Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

Funda Meric-Bernstam (F)

The University of Texas MD Anderson Cancer Center, Houston, Texas.

Philippe L Bedard (PL)

Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Alexia Iasonos (A)

Memorial Sloan Kettering Cancer Center, New York, New York.

Deborah Schrag (D)

Dana-Farber Cancer Institute, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH